Preview

Российский кардиологический журнал

Расширенный поиск

ОСТРЫЙ ИНФАРКТ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST ЭЛЕКТРОКАРДИОГРАММЫ: РЕАБИЛИТАЦИЯ И ВТОРИЧНАЯ ПРОФИЛАКТИКА

https://doi.org/10.15829/1560-4071-2015-1-6-52

Полный текст:

Аннотация

.

Об авторах

М. Г. Бубнова

Россия

проф. 

Москва



О. Л. Барбараш

проф.

Кемерово



А. А. Долецкий

к. м.н.

Москва



В. Б. Красницкий

к. м.н. 

Москва



Е. В. Лебедева

к. м.н.

Томск



Н. П. Лямина

проф.

Саратов



А. Н. Репин

проф.

Томск



А. В. Свет

к. м.н.

Москва



Г. А. Чумакова

проф. 

Барнаул



Д. М. Аронов

проф.

Москва



А. А. Абдуллаев

проф.

Махачкала



Т. П. Арутюнов

проф.

Москва



О. Л. Барбараш

проф. 

Кемерово



С. А. Бойцов

проф.

Москва



С. А. Болдуева

проф.

Санкт-Петербург



Ю. И. Бузиашвили

академик РАН 

Москва



А. С. Галявич

проф.

Казань



А. А. Гарганеева

проф.

Томск



М. Ю. Герасименко

проф.

Москва



С. Ф. Гуляева

проф.

Киров



П. Я. Довгалевский

проф.

Саратов



А. И. Журавлева

проф.

Москва



В. С. Задионченко

проф.

Москва



В. П. Зайцев

проф.

Москва



А. Н. Закирова

проф.

Уфа



Г. Е. Иванова

проф.

Москва



Д. Г. Иоселиани

член-корр. РАН

Москва



А. М. Калинина

проф.

Москва



Р. С. Карпов

академик РАН

Томск



Н. А. Козиолова

проф.

Пермь



А. Г. Куликов

проф.

Москва



В. В. Кухарчук

член-корр. РАН

Москва



К. В. Лядов

член-корр. РАН

Москва



В. П. Мазаев

проф.

Москва



А. И. Мартынов

академик РАН

Москва



О. Ф. Мисюра

к. м.н. 

Санкт-Петербург



Е. Я. Парнес

проф.

Москва



Н. Б. Перепеч

проф.

Санкт-Петербург



А. Н. Репин

проф.

Томск



М. Я. Руда

проф.

Москва



И. И. Староверов

д. м.н.

Москва



А. Б. Смулевич

академик РАН

Москва



А. Л. Сыркин

проф.

Москва



С. Н. Терещенко

проф.

Москва



И. В. Фомин

проф.

Нижний Новгород



Е. И. Чазов

академик РАН

Москва



И. Е. Чазова

член-корр. РАН

Москва



С. В. Шлык

проф.

Ростов-на-Дону



Е. В. Шляхто

академик РАН

Санкт-Петербург



В. А. Шульман

проф.

Красноярск



Список литературы

1. Аронов Д. М. Реабилитация больных, перенесших инфаркт миокарда на диспансерно-поликлиническом этапе. Методические рекомендации. Москва, МЗ СССР, 1983 г.

2. Аронов Д. М., Арутюнов Г. П., Белененков Ю. Н. и др. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора в комплексной терапии больных с хроническими формами ишемической болезни сердца. Кардиосоматика 2012; 2: 58–60.

3. Аронов Д. М., Бубнова М. Г., Новикова Н. К. и др. Современные методы реабилитации больных ИБС на постстационарном (диспансерно-поликлиническом) этапе Методические рекомендации, 2003.

4. Аронов Д. М., Красницкий В. Б., Бубнова М. Г. и др. Физические тренировки в комплексной реабилитации и вторичной профилактике на амбулаторно-поликлиническом этапе у больных ишемической болезнью сердца после острых коронарных осложнений. Российское кооперативное исследование. Кардиология 2006; 9: 33–8.

5. Аронов Д. М., Новикова Н. К., Зволинская Е. Ю., Качаров А. М., Бубнова М. Г. Физические тренировки больных ИБС в сочетании с сахарным диабетом второго типа. Методические рекомендации. Москва, 1996.

6. Аронов Д. М., Тартаковский Л. Б., Новикова Н. К. Значение три метазидина в реабилитации больных после инфаркта миокарда. Кардиология. 2002; 42 (2): 14–20.

7. Аронов Д. М., Шарфнадель М. Г. Сравнительная оценка эффективности различных методов физических тренировок больных, перенесших инфаркт миокарда. Бюллетень ВКНЦ, 1985, 2, 76–81

8. Арутюнов Г. П., Евзерихина А. В., Рылова А. К., Лобзева В. И. Клиническая эффективность разных форм непрерывного образования пациентов, страдающих хронической сердечной недостаточностью. Кардиосоматика 2013; 1: 55–61.

9. Барбараш О. Л., Лебедева Н. Б., Жукова Е. Л., Барбараш Л. С. Эффективность программы поведенческой реабилитации у больных инфарктом миокарда в зависимости от типа коронарного поведения. Кардиология 2003; 41 (12): 73–81.

10. Бойцов С. А., Чучалин А. Г. Российские рекомендации по профилактике хронических неинфекционных заболеваний, 2013.

11. Болдуева С. А., Шабров А. В., Монова И. А., Бурак Т. Я., Самохвалова М. В. Клинико-психологические факторы, влияющие на риск внезапной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия, 2007; 7: 59–68.

12. Бубнова М. Г., Аронов Д. М., Перова Н. В., Зволинская Е. Ю. Физические нагрузки и атеросклероз: влияние динамических нагрузок разной интенсивности на показатели липидтранспортной системы и углеводного обмена у больных коронарной болезнью сердца и сахарным диабетом 2 типа. Кардиология 2005; 11: 33–40.

13. Ефремушкин Г. Г., Антропова О. Н., Осипова И. В. Физическая реабилитация в комплексной терапии больных с низким сердечным выбросом. Тер архив 2003; 75 (12): 50–4.

14. Лямина Н. П., Котельникова Е. В. Компьютерные технологии в организации реабилитационных мероприятий в первичном звене здравоохранения у больных ишемической болезнью сердца. Здравоохранение Российской Федерации 2010; 5: 32–5.

15. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) 2013. Сердечная Недостаточность. 2013; 14 (7): 379–472.

16. Николаева Л. Ф., Аронов Д. М. Реабилитация больных ишемической болезнью сердца (Руководство для врачей) Москва, “Медицина”, 1988.

17. Оганов Р. Г., Деев А. Д., Жуковский Г. С. Влияние курения на смертность от хронических неинфекционных заболеваний по результатам проспективного исследования. Проф. забол. и укрепл. здоровья. 1998; 3: 13–15.

18. Организация школ здоровья для больных ишемической болезнью сердца в практическом здравоохранении. Под редакцией Оганов Р. Г., Москва,1993.

19. Ощепкова Е. В., Дмитриев В. А., Гриднев В. И., Довгалевский П. Я., Карпов Ю. А. Трёхлетний опыт работы регистра больных с острым коронарным синдромом в региональных сосудистых центрах и первичных сосудистых отделениях. Кардиологический вестник, том VII (XIX), № 1, 2012.

20. Приказ Минздравсоцразвития Российской Федерации от 22.11.04 № 230 “Об утверждении стандарта медицинской помощи больным острым инфарктом миокарда”.

21. Репин А. Н., Лебедева Е. В., Сергиенко Т. Н., Карпов Р. С. Комплексная реабилитация пациентов с ишемической болезнью сердца в сочетании с тревожно-депрессивными расстройствами. Кардиосоматика 2010; 1: 51–6.

22. Руда М. Я. с соавт. Российские рекомендации Общества специалистов по неотложной кардиологии “Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы” 2013.

23. Руда М. Я., Зыско А. П. Инфаркт миокарда, Медицина, 1991 г., 287 стр.

24. Смулевич А. Б. Депрессии при соматических и психических заболеваниях. Мед. Информ. Агентство, Москва. 2003. 429 с.

25. Сумин А. Н., Барбараш О. Л. Особенности кардиологической реабилитации в старших возрастных группах. Кардиосоматика 2012; 1: 38–43.

26. Сыркин А. Л., Новикова Н. А., Терехин С. А. Острый коронарный синдром. Мед. Информ. Агентство, Москва. 2010; 437 с.

27. Чазова И. Е. с соавт. Российские рекомендации по диагностике и лечению АГ, 2013.

28. Чумакова Г. Л., Киселева Е. В., Алешкевич В. В., Чурсина В. И. Выбор оптимальной интенсивности физических тренировок у больных с инфарктом миокарда и артериальной гипертонией. Журнал сердечная недостаточность. 2002; 5: 5–9.

29. Чукаева И. И., Орлова Н. В., Кисляк О. А. и соавт. Школы здоровья для больных сердечно-сосудистыми заболеваниями. Учебное пособие. — М.: ГОУ ВПО РГМУ, 2011; 149 с.

30. Шальнова С. А., Деев А. Д., Оганов Р. Г. Распространенность курения в России. Результаты обследования национальной представительной выборки населения. Проф. забол. и укрепл. здоровья. 1998; 3: 9–12.

31. Agewall S., Cattaneo M., Collet J. P., et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Eur Heart J. 2013; 34: 1708–15.

32. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatele ttherapy after acute coronary syndrome. N Engl J Med 2011;365 (8): 699–708.

33. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensinconverting-еzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332 (2):80–5.

34. American College of Sports Medicine (ACSM) Walking Equation ACSM’s Guidelines or Exercise Testing and Prescription; 2006.

35. Anderson JL, Adams CD. Antman EM. еt al. 2011 WRITING GROUP MEMBERS; ACCF/ AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Jun 7; 123 (22): e. 627.

36. Bangalore S, Qin J, Sloan S, et al What is optimal blood pressure in patients after acute syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin or atorVastatin Evaluation and infection Therapy-Thombolysis in Myocardial infarction (PROVE IT-TIMI) 22 trail. Circulation 2010; 122: 2142–51.

37. Beck A. Cognitive Therapy of Depression. New York: Guilford Press; 1977.

38. Belardinelli R. Benefits of the metabolic approach in cardiac rehabilitation Heart Metab 2008; 39: 25–8.

39. Berkman LF, Blumenthal J, Burg M, et al., for the Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomised Trial. JAMA 2003: 289: 3106–16.

40. Bertranda ME., Foxb KM., Remmec WJ., et.al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial Archives of Cardiovascular Disease. 2009; 102: 89–96.

41. Braunwald E. Heart disease. A Textbook of Cardiovascular Medicine. W. B. Saunders Company. Philadelphia, London, Toronto, Sydney, Tokyo; 1996.

42. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145 (1): 80–7.

43. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE) -ISCHEMIA study. Am Heart J. 2007; 153 (3): 445.e7–14.

44. Borghi C, et al. Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction (SMILE IV trial). JACC 2011; abstr.

45. Borghi C, Marino P, Zardini P et al. Short-and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J. 1998; 136 (2):213–25.

46. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.

47. Carney R. M., Blumenthal J. A., Freedland K. E. et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom. Med. 2004. 66 (Suppl.): 466–74.

48. Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology. Core components of cardiac rehabilitation/secondary prevention programs. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology. Circulation. 2000; 102: 1069–73.

49. Cooper A, Skinner J, Nherera L, et al (2007) Clinical Guidelines and Evidence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.

50. Giannuzzi P, Saner H, Bjo¨rnstad H, et al. Mendes M, Cohen-Solal A, Dugmore L, Hambrecht R, Hellemans I, McGee H, Perk J, Vanhees L, Veress G; Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J 2003; 24:1273–8.

51. Gulliksson M., Burell G., Vessby B. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care Project (SUPRIM). Arch. Intern. Med. 2011; 171: 134–40.

52. Dawood N, Vaccarino V, Reid KJ, et al. Predictors of smoking cessation after a myocardial infarction. The role of institutional smoking cessation programs in improving success. Arch. Int. Med. 2008; 168: 1961–7.

53. DeВusk R, Drory Y, Goldstein I. et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000; 86: 175–81.

54. Dickstein K, Kjekshus J. Effects of losartan captopril on mortality morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60.

55. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 855–7.

56. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet. 2002; 359: 1269–75.

57. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006; 166 (6): 659–66.

58. Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122: S640–56.

59. Fihn SD, Gardin JM Abrams J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease JACC 2012; 60 (24): e44–164.

60. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomized factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet. 1995; 345: 669–85.

61. Fox K. A. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ. 2006; 333: 1091.

62. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362:782–8.

63. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101–e98.

64. Frühbeck G, Toplak H, Woodward E, et al. Тhe Executive Committee of the European Association for the Study of Obesity Obesity: The Gateway to Ill Health — an EASO Position Statement on a Rising Public Health, Clinical and Scientific Challenge in Europe Obes Facts 2013; 6: 117–120.

65. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002; 288: 701–9.

66. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intem Med. 2003; 163 (19): 2345–53.

67. Green LA., Arbor A, Dickinson WP et al. AAFP Guideline for the Detection and Management of Post–Myocardial Infarction Depression Ann Fam Med 2009; 7:71–9. DOI: 10.1370/afm.918.

68. Goble AJ, DL Hare, PS Macdonald, RS Oliver, MA Reid, MC Worcester Effect of early programmes of high and low intensite exercise on physical performance after transmural acute myocardial infarction Br Heart J 1991; 65: 126–31.

69. Cooper A, Skinner J, Nherera L, et.al. 2007. Clinical Guidelines and Evidence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. NICE guideline Post MI Full Guideline 2007.

70. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343: 1115–22.

71. Giuseppe MG, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension Eur Heart J, 2013. doi:10.1093/eurheartj/eht151.

72. Hassan Y, Kassab Y, Abd Aziz N, Akram H. Ismail O. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther. 2013 Apr; 38 (2): 97–100.

73. Heidbuchel H, Verhamme P., Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation (EHRA) Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary Europace, 2013; 15: 625–51.

74. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989; 299:1187–92.

75. Honig A, Kuyper AM, Schene AH, et al. Treatment of postmyocardial infarction depressive disorder: a randomized, placebocontrolled trial with mirtazapine. Psychosom Med. 2007; 69: 606–13.

76. Iyengar SS., Rosano G. M.C. Effect Antianginal Drug in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial infarction. Am J Cardiovasc Drugs 2009; 9 (5); 293–297.

77. James S, Roe M, Cannon CP, et.al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for noninvasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Br Med J 2011; 342: d3527.

78. James PA., Oparil S, Carter BL. et.al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. doi:10.1001/jama.2013.284427.

79. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation J Am Coll Cardiol 2014; doi: 10.1016/j. jacc.2014.03.022.

80. Jensen MMD, Ryan DH., Apovian CM., et.al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: AReport of the American College of Cardiology/American Heart Association Task Force onPractice Guidelines and The Obesity Society published online November 12, 2013 Circulation. Print ISSN: 0009–7322. Online ISSN: 1524–4539 http://circ.ahajournals.org/ content/early/2013/11/11/01. cir.0000437739.71477.ee.citation

81. Joliffe J. A., Rees K., Taylor R. S. et al. Exercise-based rehabilitation for coronary heart disease, 2002. Oxford: Update Software.

82. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 2014;100: ii1–ii67.

83. Kristensen S, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J 2014; 35: 1957–70.

84. Kostis JB, Jackson G, Rosen R. et al. R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005; 96: 313–21.

85. Køber L, Torp-Pedersen C, Carlsen JE et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfuction after myocardial infarction. N Engl J Med 1995; 33: 1670–6.

86. Leon A. S., Franklin B. A., Costa F. et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005; 111: 369–76.

87. Levine GN, Steinke EE, Bakaeen FG. et.al. Sexual Activity and Cardiovascular Disease A Scientific Statement from the American Heart Association. Circulation, 2012; 125: 1058–72.

88. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007; 297: 367–79.

89. Lip GY, Huber K, Andreotti F, et.al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary — a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311–8.

90. Lyamina N. P., Manukhina E. B. Dovney F., Lyamina S. V. Beneficial effects of adaptation to hypoxia in patients with ischemic heart disease and extra systolic arrhythmias. J. Mol. Cell. Cardiо, 2007; 42 (supp. l1): 9–12.

91. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34 (28): 2159–219.

92. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) — Prevenzione. Circulation. 2002;105 (16):1897–1903.

93. Martin BJ; Hauer T; Агепа R; Austford LD.; Diane P.G; et al. Cardiac Rehabilitation Attendance and Outcomes in Coronary Artery Disease Patients. Circulation 2012; 26 (6): 677–87.

94. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. ATLAS ACS 2–TIMI 51 Investigators. N Engl J Med. 2012; 366: 9–19.

95. Mo¨ller J, Ahlbom A, Hulting J. et al. Sexual activity as a trigger of myocardial infarction: a case-crossover analysis in the Stockholm Heart Epidemiology Programmer (SHEEP). Heart. 2001; 86: 387–90.

96. Montalescot G, Sechtem U, Achenbach S 2013 ESC guidelines on the management of stable coronary artery disease Eur Heart J 2013; doi:10.1093/eurheartj/eht296.

97. Moser M, Olivier CB, Bode C. Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J. 2014; 35: 216–23.

98. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med. 1990; 322:743–53.

99. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 4 (8): 803–869.

100. Nahm ES, Blum K, Scharf B et al. Exploration of patients’ readiness for an eHealth management program for chronic heart failure: a preliminary study. J Cardiovasc Nurs. 2008; 23 (6): 463–71.

101. Nehra A, Jackson G, Miner M et al. R. The Princeton III Consensus Recommendations for the Management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78.

102. O’Gara P.T., Kushner F. G., Ascheim, DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. / JACC 2013; 61 (4): e78-e140.

103. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. EurHeart J 2011; 32: 2781–9.

104. Ory MG, Peck BM, Browning C, Furjuoh SN. Lifestyle discussions during doctor-older patient interactions: the role of time in the medical encounter. MedGenMed, 2007; 9 (4): 48.

105. Pfeffer MA, Braunwald E, Moye LA et al, Effect of captopril on mortality and morbidity in patients with left ventricular dysfuction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.

106. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349 (20):1893–906.

107. Perk J, Backer GD. Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J, 2013; doi:10.1093/eurheartj/ ehs092.

108. Physical activity guidelines advisery committee (PAGAC) /Physical activity guidelines advisery committee report, 2008, Washington DC, US, Department of health and human services, 2008.

109. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348 (14): 1309–21.

110. Pitt B., White H., Nicolau J. et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol., 2005;46:425–31.

111. Rea TD, Heckbert SR, Kaplan RC et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann. Intern. Med. 2002; 137 (6): 494–500.

112. Rehabilitation after cardiovascular diseases with special emphasis on developing country. A report of a WHO Committee. World Health Organ. Tech. Rep. Ser. 1993; 831: 1–122.

113. Rees K, Bennett P, West R, Davey Smith G, Ebrahim S. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews 2004; Issue 2. Art No: CD002902. DOI: 10.1002/14651858. CD002920.pub2.

114. Rognmo О.; Moholdt T.; Bakken H.; Hole T.; Molstad P.; Myhr N.; Grimsmo J.; Wisloff U.. Cardiovascular Risk of High-Versus Moderate-Intensity Aerobic Exercise in Coronary Heart Disease Patients. Circulation 2012; 126 (12): 1436–40.

115. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEJM 2005; 352: 1179–89.

116. Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J of Cardiology 2012; 59: 14–21.

117. Scrutinio D, Temporelli PL, Passantino A, Giannuzzi P. Long-term Secondary Prevention Programs After Cardiac Rehabilitation for the Reduction of Future Cardiovascular Events: Focus on Regular Physical Activity Future Cardiol. 2009; 5 (3): 297–314.

118. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2011;58:2432–46.

119. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infraction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821–828.

120. Steg P. G., James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J.; 2012; 33: 2569–619.

121. Steinke EE, Jaarsma T, Barnason SA, et al Sexual Counselling for Individuals With Cardiovascular Disease and Their Partners A Consensus Document From the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP) European Heart Journal2013July 29, doi:10.1093/eurheartj/eht270.

122. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 2013; http://circ.ahajournals.org/content/early/2013/11/11/01. cir.0000437738.63853.7a.citation.

123. Taylor R. S., Brown A., Ebrahim S. et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am. J. Med. 2004; 116: 682–92.

124. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62: 792–8.

125. Thompson DR, Webster RA, Cordle CJ, et al. Specific sources and patterns of anxiety in male patients with first myocardial infarction. Br J Med Psychol 1987; 60: 343–48.

126. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 update: performance measures on cardiac rehabilitation for referral to cardiac rehabilitation/secondary prevention services. Circulation. 2010;122: 1342–50.

127. The GRACE Investigators, GRACE: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001; 141: 190–9.

128. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9–12.

129. Vandvik PO, Lincoff AM, Gore JM., et al. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2) (Suppl): e637S–e68S.

130. Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology: Secondary prevention through cardiac rehabilitation. Eur. Heart J. 2003; 24: 1272–8.

131. WHO. Rehabilitation of patients with cardiovascular disease. Report of WHO Expert Committee, 1964. WHO Technical Report Series No 270. Geneva: WHO.

132. White book on physical and rehabilitation medicine in Europe, 2006. Editors: Gutenbrunner C., Ward AB, Chamberlain MA.

133. You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 2): e531S–e575S.

134. Yusuf S, Sleight P, Pogue J et.al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342 (3): 145–53.


Для цитирования:


Бубнова М.Г., Барбараш О.Л., Долецкий А.А., Красницкий В.Б., Лебедева Е.В., Лямина Н.П., Репин А.Н., Свет А.В., Чумакова Г.А., Аронов Д.М., Абдуллаев А.А., Арутюнов Т.П., Барбараш О.Л., Бойцов С.А., Болдуева С.А., Бузиашвили Ю.И., Галявич А.С., Гарганеева А.А., Герасименко М.Ю., Гуляева С.Ф., Довгалевский П.Я., Журавлева А.И., Задионченко В.С., Зайцев В.П., Закирова А.Н., Иванова Г.Е., Иоселиани Д.Г., Калинина А.М., Карпов Р.С., Козиолова Н.А., Куликов А.Г., Кухарчук В.В., Лядов К.В., Мазаев В.П., Мартынов А.И., Мисюра О.Ф., Парнес Е.Я., Перепеч Н.Б., Репин А.Н., Руда М.Я., Староверов И.И., Смулевич А.Б., Сыркин А.Л., Терещенко С.Н., Фомин И.В., Чазов Е.И., Чазова И.Е., Шлык С.В., Шляхто Е.В., Шульман В.А. ОСТРЫЙ ИНФАРКТ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST ЭЛЕКТРОКАРДИОГРАММЫ: РЕАБИЛИТАЦИЯ И ВТОРИЧНАЯ ПРОФИЛАКТИКА. Российский кардиологический журнал. 2015;(1):6-52. https://doi.org/10.15829/1560-4071-2015-1-6-52

For citation:


Bubnova M.G., Barbarash O.L., Doletsky A.A., Krasnitsky V.B., Lebedev E.V., Lyamina N.P., Repin A.N., Light A.V., Chumakov G.A., Aronov D.M., Abdullaev A.A., Arutyunov T.P., Barbarash O.L., Boytsov S.A., Boldueva S.A., Buziashvili Y.I., Galyavich A.S., Garganeeva A.A., Gerasimenko M.Y., Gulyaeva S.F., Dovgalevsky P.Y., Zhuravlev A.I., Zadionchenko V.S., Zaitsev V.P., Zakirova A.N., Ivanov G.E., Iosseliani D.G., Kalinina A.M., Karpov R.S., Kosilov N.A., Kulikov G.A., Kuharchuk V.V., Lyadov K.V., Mazaev V.P., Martynov A.I., Misyura O.F., Parnes E.J., Perepech N.B., Repin A.N., Ruda M.Y., Old Believers I.I., Smulevich A.B., Syrkin A.L., Tereshchenko S.N., Fomin I.V., Chazov E.I., Chazova I.E., Shlyk S.V., Shlyakhto E.V., Shulman V.A. ACUTE ST ELEVATION MYOCARDIAL INFARCTION: AFTERCARE AND SECONDARY PREVENTION. NATIONAL RUSSIAN GUIDELINES. Russian Journal of Cardiology. 2015;(1):6-52. (In Russ.) https://doi.org/10.15829/1560-4071-2015-1-6-52

Просмотров: 943


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)